Inhibition of TGFBR1 can block the activation of fibroblasts mediated via IL1B/TGFB1 and reduce the secretion of pro-inflammatory cytokines in colorectal cancer, which would make the cancer cells more sensitive to chemotherapy. Here, TGFBR1 is linked to cancer.